FDA Approved: RIABNI — Original Application (Amgen, Inc)

View source ↗

Summary

FDA approved RIABNI (rituximab-arrx) from Amgen as a biosimilar to rituximab via Original Application.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Follicular Lymphoma
• Granulomatosis with Polyangiitis
• Microscopic Polyangiitis
• Non-hodgkin Lymphoma
• Rheumatoid Arthritis
• Small Lymphocytic Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• RIABNI (RITUXIMAB-ARRX)

Snippet

ORIG AP for RIABNI (RITUXIMAB-ARRX)